GT BIOPHARMA, INC. Debt Securities, Available-for-sale, Realized Loss
GT BIOPHARMA, INC. (GTBP) reported Debt Securities, Available-for-sale, Realized Loss of -$30.00 thousand for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-15.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss · last filed 2022-08-15
- GT BIOPHARMA, INC. debt securities, available-for-sale, realized loss for the quarter ending 2022-06-30 was $12.00K.
- GT BIOPHARMA, INC. debt securities, available-for-sale, realized loss for the quarter ending 2022-03-31 was -$42.00K.
| Period end | Debt Securities, Available-for-sale, Realized Loss 3 month | Debt Securities, Available-for-sale, Realized Loss 6 month | Debt Securities, Available-for-sale, Realized Loss 12 month |
|---|---|---|---|
| 2022-06-30 | $12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$30.00K 10-Q · filed 2022-08-15 | |
| 2022-03-31 | -$42.00K 10-Q · filed 2022-05-16 | ||
| 2021-12-31 | -$29.00K 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |